rs730882256
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_020919.4(ALS2):c.4573dupG(p.Val1525GlyfsTer17) variant causes a frameshift change. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_020919.4 frameshift
Scores
Clinical Significance
Conservation
Publications
- ALS2-related motor neuron diseaseInheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
- amyotrophic lateral sclerosis type 2, juvenileInheritance: AR Classification: STRONG Submitted by: Genomics England PanelApp
- infantile-onset ascending hereditary spastic paralysisInheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Orphanet
- juvenile primary lateral sclerosisInheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Orphanet
- juvenile amyotrophic lateral sclerosisInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| ALS2 | NM_020919.4 | c.4573dupG | p.Val1525GlyfsTer17 | frameshift_variant | Exon 29 of 34 | ENST00000264276.11 | NP_065970.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| ALS2 | ENST00000264276.11 | c.4573dupG | p.Val1525GlyfsTer17 | frameshift_variant | Exon 29 of 34 | 1 | NM_020919.4 | ENSP00000264276.6 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Infantile-onset ascending hereditary spastic paralysis Pathogenic:2
- -
The homozygous p.Val1525GlyfsTer17 variant in ALS2 was identified by our study in 1 individual with infantile-onset ascending hereditary spastic paralysis. The variant has been reported in 3 Turkish individuals with infantile-onset ascending hereditary spastic paralysis (PMID: 24562058, 33155358), segregated with disease in 1 affected relatives from 1 family (PMID: 24562058), and was absent from large population studies. This variant has been reported in ClinVar (Variation ID: 183240) as pathogenic by OMIM and as likely pathogenic by Cirak Lab, University Hospital Cologne. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 1525 and leads to a premature termination codon 17 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the ALS2 gene is an established disease mechanism in autosomal recessive infantile-onset ascending hereditary spastic paralysis. The presence of this variant in 3 affected homozygotes and in 3 individuals with infantile-onset ascending hereditary spastic paralysis increases the likelihood that the p.Val1525GlyfsTer17 variant is pathogenic (PMID: 24562058). In summary, this variant meets criteria to be classified as pathogenic for infantile-onset ascending hereditary spastic paralysis in an autosomal recessive manner based on the predicted impact of the variant, its absence from control populations, and multiple homozygous occurrences in affected individuals. ACMG/AMP Criteria applied: PVS1, PM2, PM3, PP1 (Richards 2015). -
Amyotrophic lateral sclerosis type 2, juvenile Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at